[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@ohadhammer Ohad Hammer
Ohad Hammer posts on X about $gmab, $lly, $8750t, $bntx the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXXX +1,833%
- X Months XXXXXXX +39%
- X Year XXXXXXX -XXXX%
Mentions: X #
- X Week X -XX%
- X Month X -XX%
- X Months XX +94%
- X Year XX +6.10%
Followers: XXXXX #
- X Week XXXXX +0.11%
- X Month XXXXX +2.10%
- X Months XXXXX +8.50%
- X Year XXXXX +15%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks
Social topic influence $gmab #1, $lly #32, $8750t #7, $bntx, $zlab
Top accounts mentioned or mentioned by @adar170 @jacobplieth @rnaianalyst @monacobiotech @egutlederer @apexonco @andrewpannu @diaamahmoud @chiragontwtr @bigpharmaguy @nournaim88 @jq1234t @bertrandbio @johnbresnahan @raffcolo @rspharmdphd @myesmo @gerardcaelles @sciencescanner @biopharmiq
Top assets mentioned Eli Lilly and Company (LLY)
Top Social Posts #
Top posts by engagements in the last XX hours
"Great M&A slides from Lifesci Capital. Interesting to see acquirers are mostly interested in "unique" programs in term of biology (new mechanisms platforms and modalities) or stage (first in class) with limited appetite for more incremental improvements or less differentiated assets that are very popular with investors (bispecifics ADCs radiopharma half life extended biologics etc)"
X Link @ohadhammer 2025-10-14T21:25Z 7901 followers, 100.7K engagements
"2nd line NSCLC therapies from Cowen's note on $BNTX/ $GMAB shows how hard it is to beat Taxotere in this setting. No agent was able to show a meaningful PFS benefit in the overall population anti-PD1s added 3-4 months in OS and TROP2 ADCs failed to demonstrate clinically meaningful benefit"
X Link @ohadhammer 2024-06-03T10:42Z 7903 followers, 9711 engagements
"Fascinating dynamics in ovarian cancer with multiple ADC programs demonstrating a XX% ORR. FRa in the lead ( $GMAB and $LLY in P3s AZ reported today) CDH6 in P2 (Daiichi reporting P2 data later today) and NaPi2b (Tubulis presented strong results today) in P1. All programs are topo1-based so whoever reaches the market first could render most other programs (15 in the clinic) irrelevant assuming efficacy stays similar #ESMO25"
X Link @ohadhammer 2025-10-19T11:28Z 7901 followers, 25.7K engagements
"Similar story in SCLC with ADCs targeting B7H3 DLL3 SEZ6 all reporting strong efficacy. 15+ programs in the clinic most will finish the race empty handed (Table from Jefferies' note on $ZLAB)"
X Link @ohadhammer 2025-10-22T06:32Z 7901 followers, 16.6K engagements